AB103

DRUG2 trials

Sponsors

Atox Bio Ltd

Conditions

Healthy Volunteer Safety StudyNecrotizing Soft Tissue Infections

Phase 1

AB103 Peptide Antagonist in Healthy Volunteers

CompletedNCT01166984

Atox Bio LtdHealthy Volunteer Safety Study

Start: 2010-09-30End: 2011-06-30Updated: 2021-06-09

Phase 2

Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections Patients

CompletedNCT01417780

Atox Bio LtdNecrotizing Soft Tissue Infections

Start: 2011-12-31End: 2012-09-30Updated: 2021-08-18

Related Papers

A Novel Drug for Treatment of Necrotizing Soft-Tissue Infections

JAMA Surgery2014-04-1689 citations